Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects

Journal of Clinical Pharmacology

Volumn 48, Issue 11, 2008, Pages 1289-1299

  Marier, Jean Francois ^a   Beliveau, Martin ^a   Mouksassi, Mohamad Samer ^a   Shaw, Paula ^b   Cyran, Jane ^c   Kesavan, Jothi ^c   Wallens, John ^c   Zahir, Hamim ^c,d   Wells, David ^c,e   Caminis, John ^c,f  

^a PHARSIGHT CORPORATION   (Canada)

^b Northwest Kinetics   (United States)

^c NPS Pharmaceuticals   (United States)

^d DAIICHI SANKYO INC   (United States)

^e Drug Metabolism and Pharmacokinetics   (United States)

^f Eurand Pharmaceuticals Inc   (United States)

Author keywords

Multiple ascending dose; Pharmacokinetics; Safety and tolerability; Subcutaneous; Teduglutide

Indexed keywords

TEDUGLUTIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER;

ADMINISTRATION, CUTANEOUS; ADULT; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; MALE; MIDDLE AGED; PEPTIDES; YOUNG ADULT;

EID: 54049138493     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008320605     Document Type: Article

References (20)

1. Munroe DG, Gupta AK, Kooshesh F., et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999 ; 96: 1569-1573.
2. Tavares W., Drucker DJ, Brubaker PL Enzymatic- and renal-dependent catabolism of the intestinotrophic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab. 2000 ; 278: E134 - E139.
3. Martin GR, Beck PL, Sigalet DL Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol. 2006 ; 12: 4117-4129.
4. Wallis K., Walters JR, Forbes A. Review article: glucagon-like peptide 2-current applications and future directions. Aliment Pharmacol Ther. 2007 ; 25: 365-372.
5. Jeppesen PB, Sanguinetti EL, Buchman A., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005 ; 54: 1224-1231.
6. Protocol Clo600-006. A phase I, randomized, two-way crossover bioavailability study of 0.12 mg/kg ALX-0600 in normal healthy subjects. September 2003.
7. Protocol Cl0600-015. A phase I, randomized, open-label, 3-way crossover bioavailability study of 10 mg teduglutide in healthy adults. July 2005.
8. Ferrone M., Scolapio JS Teduglutide for the treatment of short bowel syndrome. Ann Pharmacother. 2006 ; 40: 1105-1109.
9. Ferguson A. Ulcerative colitis and Crohn's disease: important and disabling diseases, still under researched. BMJ. 1994 ; 309: 355-356.
10. Scribano ML, Prantera C. Review article: medical treatment of active Crohn's disease. Aliment Pharmacol Ther. 2002 ; 16 (suppl 4). 35-39.
11. Hanauer SB, Sandborn WJ ; The Practice Parameters Committee of the ACG. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 ; 96: 635-643.
12. Rowland M., Tozer TN Clinical Pharmacokinetics: Concepts and Application. 3 rd ed. Baltimore: Williams & Wilkins ; 1994.
13. Smith BP, Vandenhende FR, Desante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000 ; 17: 1278-1283.
14. Chow SC, Liu JP Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker ; 1992.
15. Rosenzweig P., Miget N., Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol. 1999 ; 48: 19-23.
16. Shetty A., Forbes A. Pharmacogenomics of response to antitumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenomics. 2002 ; 2: 215-221.
17. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 ; 46: 3151-3158.
18. Sandborn WJ, Targan SR Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002 ; 122: 1592-1608.
19. Hartmann B., Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000 ; 85: 28842888.
20. DaCambra MP, Yutsa B., Sumner-Smith M., et al. Structural determinants for activity of glucagon-like peptide-2. Biochemistry. 2000 ; 39: 8888-8894.